title: Outcomes and complications of excimer laser surgery in patients with collagen vascular and other immune-mediated inflammatory diseases.
abstract: To assess refractive and visual outcomes and postoperative complications in a large number of patients with well-controlled collagen vascular and other immune-mediated inflammatory diseases.
  
  
  
  Optical Express, Glasgow, United Kingdom.
  
  
  
  Retrospective case series.
  
  
  
  The files were reviewed of patients who had collagen vascular and other immune-mediated inflammatory diseases and who had excimer laser surgery between 2008 and 2015. In all cases, the disease was well controlled with no flare or symptoms for a minimum of 6 months preoperatively.
  
  
  
  The study comprised 622 patients (1224 eyes) with 1 of the following underlying diseases: rheumatoid arthritis (50.6% of patients), systemic lupus erythematosus (19.5%), psoriatic arthritis (10.5%), sarcoidosis (10.0%), ankylosing spondylitis (6.4%), multiple sclerosis (1.9%), or scleroderma (1.1%). Laser in situ keratomileusis (LASIK) was performed in 1114 eyes (91.0%) and photorefractive keratectomy (PRK) in 110 eyes (9.0%). The mean follow-up was 10.9 months. The preoperative spherical equivalent ranged between -10.13 diopters (D) and +4.13 D (LASIK) and -9.50 D and +4.00 D (PRK). Postoperatively, 81.8% LASIK eyes and 82.3% PRK eyes were within ±0.50 D. The uncorrected distance visual acuity was 20/20 or better in 76.8% and 73.4%, respectively. Complications were mostly those that would be expected after excimer laser surgery in a population of patients without disease with the exception of 1 peripheral flap melt that responded to treatment with topical steroids.
  
  
  
  Excimer laser surgery can be safely performed in patients with well-controlled collagen vascular or other immune-mediated inflammatory disease.
  
  
  
  Dr. S.C. Schallhorn is a consultant to Abbott Medical Optics, Inc., Acufocus, Inc., and Carl Zeiss Meditec AG, and a global medical director for Optical Express. No other author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: From the Department of Ophthalmology (J.M. Schallhorn, S.C. Schallhorn), University of California, San Francisco, and the Roski Eye Institute (S.C. Schallhorn), University of Southern California, Los Angeles, California, USA; Optical Express (S.C. Schallhorn, Hettinger, Venter, Pelouskova, Teenan, Hannan), London, United Kingdom. Electronic address: Julie.schallhorn@ucsf.edu.
authors.forename: Julie M
authors.initials: JM
authors.lastname: Schallhorn
authors.affiliation: From the Department of Ophthalmology (J.M. Schallhorn, S.C. Schallhorn), University of California, San Francisco, and the Roski Eye Institute (S.C. Schallhorn), University of Southern California, Los Angeles, California, USA; Optical Express (S.C. Schallhorn, Hettinger, Venter, Pelouskova, Teenan, Hannan), London, United Kingdom.
authors.forename: Steven C
authors.initials: SC
authors.lastname: Schallhorn
authors.affiliation: From the Department of Ophthalmology (J.M. Schallhorn, S.C. Schallhorn), University of California, San Francisco, and the Roski Eye Institute (S.C. Schallhorn), University of Southern California, Los Angeles, California, USA; Optical Express (S.C. Schallhorn, Hettinger, Venter, Pelouskova, Teenan, Hannan), London, United Kingdom.
authors.forename: Keith A
authors.initials: KA
authors.lastname: Hettinger
authors.affiliation: From the Department of Ophthalmology (J.M. Schallhorn, S.C. Schallhorn), University of California, San Francisco, and the Roski Eye Institute (S.C. Schallhorn), University of Southern California, Los Angeles, California, USA; Optical Express (S.C. Schallhorn, Hettinger, Venter, Pelouskova, Teenan, Hannan), London, United Kingdom.
authors.forename: Jan A
authors.initials: JA
authors.lastname: Venter
authors.affiliation: From the Department of Ophthalmology (J.M. Schallhorn, S.C. Schallhorn), University of California, San Francisco, and the Roski Eye Institute (S.C. Schallhorn), University of Southern California, Los Angeles, California, USA; Optical Express (S.C. Schallhorn, Hettinger, Venter, Pelouskova, Teenan, Hannan), London, United Kingdom.
authors.forename: Martina
authors.initials: M
authors.lastname: Pelouskova
authors.affiliation: From the Department of Ophthalmology (J.M. Schallhorn, S.C. Schallhorn), University of California, San Francisco, and the Roski Eye Institute (S.C. Schallhorn), University of Southern California, Los Angeles, California, USA; Optical Express (S.C. Schallhorn, Hettinger, Venter, Pelouskova, Teenan, Hannan), London, United Kingdom.
authors.forename: David
authors.initials: D
authors.lastname: Teenan
authors.affiliation: From the Department of Ophthalmology (J.M. Schallhorn, S.C. Schallhorn), University of California, San Francisco, and the Roski Eye Institute (S.C. Schallhorn), University of Southern California, Los Angeles, California, USA; Optical Express (S.C. Schallhorn, Hettinger, Venter, Pelouskova, Teenan, Hannan), London, United Kingdom.
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Hannan
mesh_terms: D001327:Autoimmune Diseases / Q000150:complications*; D003094:Collagen; D003315:Cornea; D006801:Humans; D020731:Keratomileusis, Laser In Situ; D054018:Lasers, Excimer; D009216:Myopia / Q000209:etiology / Q000628:therapy*; D018903:Photorefractive Keratectomy; D012029:Refraction, Ocular; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D003094:Collagen